RNS Number:4058P
BioProgress PLC
04 September 2003


Press Release                                                  4 September 2003





                             BioProgress plc

                Interim Results - Monday 15 September 2003


BioProgress plc, a provider of innovative delivery mechanisms for the
pharmaceutical oral dosage markets, will be announcing its maiden Interim
Results for the six months ended 30 June 2003 on Monday 15 September 2003.



A meeting for analysts will be held at 09.00 a.m. at the offices of Bankside,
St. Mary Abchurch House, 123 Cannon Street, London, EC4 on Monday 15 September
2003.



                                    - Ends -



Enquiries:


Bankside
Henry Harrison-Topham / Heather Salmond               Tel: +44 (0) 20 7444 4140
henry.ht@bankside.com                                          www.bankside.com



Notes to editors:

BioProgress listed on AIM in May 2003 and is engaged in the research,
development, and design of patented encapsulation systems that use water soluble
and biodegradable films for the dietary supplement, pharmaceutical and other
sectors. The Company holds 15 patents with a further 38 pending and has product
development agreements with several global companies.  BioProgress aims to
provide a cost effective and animal-free encapsulation process for
pharmaceutical drugs in liquids, tablets and powders, thereby addressing the
needs of the entire market for oral dosage forms while providing novel delivery
mechanisms not possible with traditional processes.



The Company has also developed patented and licensed the world's first flushable
ostomy pouch that offers a newly enhanced quality of life not previously
possible for the end user. Market research shows the global ostomy market to be
worth $1 billion annually.



BioProgress's business model provides it with several significant revenue
streams including sales of encapsulating machines and film, plus licence and
fees for research development services.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NORNKQKKQBKDQCK